Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on the development of novel therapeutics for the treatment of a variety of immunological disorders, will be presenting at this year’s tenth annual C21 BioVentures Conference in Napa, CA. C21 is a private lifescience company conference aimed at fostering relationships within the biotechnology, pharmaceutical, and venture capital industries. This year’s C21 will be held at The Meritage Resort at Napa from May 20th to May 22nd.

Francois-Xavier Frapaise MD, CEO and President of Asphelia, will introduce Asphelia’s core-assets – namely, a trichuris suis ova-based therapy (ASP 1002) and an oral integrin antagonist (ASP 2002). Dr. Frapaise’s presentation will be focused on the immunomodulating effects of Helminths and the use of this novel therapeutic approach in the treatment of immunological disorders, such as Crohn’s Disease, Multiple Sclerosis, as well as allergic conditions. The Helminths technology is currently being assessed in several clinical studies being conducted globally.

About Asphelia Pharmaceuticals, Inc.

Asphelia Pharmaceuticals is a privately-held, clinical-stage company poised to change the course of immunological disorders. Asphelia’s primary focus lies in its development of therapies targeting Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis), as well as other immunological and inflammatory disorders, including multiple sclerosis and asthma. Asphelia’s lead compounds target the cause of Inflammatory Bowel Disease, not just its symptoms, in an effort to change the course of the diseases and provide patients with new freedoms.

Asphelia Pharmaceuticals, Inc.
Xavier Frapaise, 858-731-8520
xfrapaise@aspheliapharma.com

Comments

comments